February 2023 – PHAGElogist

BiomX reports “impressive” data in first bacteriophage trial

Hope that bacteriophages could represent a new therapeutic strategy for resistant bacterial infections has been bolstered by a study conducted by BiomX in cystic fibrosis (CF) patients. While still early,…

Phage Therapy in Germany-Latest

Phage Therapy in Germany—Update 2023 by Willy et al. Viruses 2023, 15(2), 588; https://doi.org/10.3390/v15020588 Abstract Bacteriophage therapy holds promise in addressing the antibiotic-resistance crisis, globally and in Germany. Here, we provide an overview…

Bacteriophage endolysin powders for therapy

A new article punished in the International Journal of Pharmaceutics describes the "Bacteriophage endolysin powders for inhaled delivery against pulmonary infections" by Wang et al. https://doi.org/10.1016/j.ijpharm.2023.122679 Abstract Endolysins are bacteriophage-encoded…

Targeting Phage Therapy 2023

The 6th World Congress on Targeting Phage Therapy 2023 will take place on June 1-2 at IRIS, Paris, France. Targeting Phage 2023: Questions, Controversies, and What is Next? Targeting Phage…

Regulatory pathway needs to be developed to make the most of phages

A regulatory pathway needs to be developed if the UK is to reap the benefits of bacteriophage therapy, Applied Microbiology International (AMI) has warned. France, Belgium and Poland are already…

Publish in this special issue to communicate your phage research

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Microbiology". Deadline for manuscript submissions: 12 May 2023 Special Issue "Bacteriophages: Infection, Genetics and Therapy" https://www.mdpi.com/journal/life/special_issues/196IPXRO2G Dear Colleagues, Bacteriophages…